Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.8704
$0.01521.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.05% | -19.46% | -17.34% | 42.49% | 2.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.67% | -26.82% | -28.28% | 13.42% | -17.76% |
| Operating Income | 34.67% | 26.82% | 28.28% | -13.42% | 17.76% |
| Income Before Tax | 33.17% | 26.19% | 32.89% | -8.43% | 22.21% |
| Income Tax Expenses | 202.17% | -- | 15.63% | 146.67% | -154.76% |
| Earnings from Continuing Operations | 33.09% | 26.27% | 32.87% | -8.49% | 22.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.09% | 26.27% | 32.87% | -8.49% | 22.30% |
| EBIT | 34.67% | 26.82% | 28.28% | -13.42% | 17.76% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 52.44% | 48.44% | 50.72% | 20.75% | 37.64% |
| Normalized Basic EPS | 52.54% | 48.38% | 50.74% | 20.77% | 37.55% |
| EPS Diluted | 52.44% | 48.44% | 50.72% | 20.75% | 37.64% |
| Normalized Diluted EPS | 52.54% | 48.38% | 50.74% | 20.77% | 37.55% |
| Average Basic Shares Outstanding | 40.74% | 43.01% | 36.19% | 36.89% | 24.58% |
| Average Diluted Shares Outstanding | 40.74% | 43.01% | 36.19% | 36.89% | 24.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |